Liraglutide has also been found to improve plaque stability and hinder atherosclerotic plaque development in apolipoprotein-E-deficient (ApoE−/−) mice by suppressing endothelial dysfunction and the expression of vascular adhesion molecules (Figure 2) [162]. The gene discussed is APOE; the disease is endothelial dysfunction.